A Study LY2228820 for Recurrent Ovarian Cancer

• Status: Completed
• Trial end date: 2018-05-11
• Target enrollment: 0
• Participant gender: Female

Summary

A study for women with ovarian cancer that has returned at least 6 months after platinum-based chemotherapy.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Carboplatin; Gemcitabine

Criteria

Inclusion Criteria:

• Have been diagnosed with ovarian, fallopian tube, or primary peritoneal cancer

• Have been treated one time with a platinum-based chemotherapy and your disease has come back at least six months after you completed treatment

• Are able to swallow tablets

• Have given written informed consent prior to any study procedures

• Have adequate blood counts, hepatic and renal function

• Have performance status equal to or less than 2 on Eastern Cooperative Oncology Group (ECOG) scale

• Have negative pregnancy test, and if participant is of child bearing potential must use birth control while on study and for three months after stopping study drug

Exclusion Criteria:

• Have been previously treated with Gemcitabine for ovarian, fallopian tube or primary peritoneal cancer

• Are currently enrolled or discontinued less than 14 days from another clinical trial

• Have a history of inflammatory bowel disease (Crohn's disease or ulcerative colitis)

• Have taken certain medications or had grapefruit juice within 7 days of initial dose of study drug, as levels of the study drug may be affected.

• Must not be pregnant or breastfeeding.

• Have malignancy or metastasis of the central nervous system

• Have borderline malignancy